This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Tyrer, P.
Right arrow Articles by Barczak, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tyrer, P.
Right arrow Articles by Barczak, P.

The British Journal of Psychiatry 168: 457-461 (1996)
© 1996 The Royal College of Psychiatrists

A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms

P Tyrer, B Ferguson, C Hallstrom, M Michie, S Tyrer, S Cooper, R Caplan and P Barczak
St Charles Hospital, London.

BACKGROUND. The possibility that treatment with tricyclic antidepressants, in the form of dothiepin, might attenuate benzodiazepine withdrawal symptoms was investigated in a double-blind trial. METHOD. Eighty-seven non-depressed psychiatric out-patients with putative normal dose benzodiazepine dependence had their benzodiazepines reduced in stepwise amounts of 20% of the original dose for eight weeks. The patients were randomised to receive dothiepin (with dosage increasing to 150 mg/day) or placebo as an aid to withdrawal before benzodiazepine reduction and these drugs were taken for four further weeks before being stopped. RESULTS. Fewer patients entered and completed the study than expected and a Type II error was possible in the results. Although there was some evidence of withdrawal symptoms being less marked in those patients allocated to dothiepin this was independent of any antidepressant effect as depression scores were lower in the placebo group in the early phase of withdrawal (P < 0.01). Of those completing the study, greater satisfaction (P = 0.03) was recorded by those who had received dothiepin; no other differences reached statistical significance. CONCLUSIONS. Dothiepin (and by implication other tricyclic antidepressants) might have some value in reducing benzodiazepine withdrawal symptoms but does not aid drug withdrawal.


This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
R. C. O. Voshaar, J. E. Couvee, A. J. L. M. Van Balkom, P. G. H. Mulder, and F. G. Zitman
Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
The British Journal of Psychiatry, September 1, 2006; 189(3): 213 - 220.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. R. Lingford-Hughes, S. Welch, and D. J. Nutt
Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology
J Psychopharmacol, September 1, 2004; 18(3): 293 - 335.
[PDF]

Home page
 Br. J. PsychiatryHome page
F. G. ZITMAN and J. E. COUVEE
Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: Report on behalf of the Dutch Chronic Benzodiazepine Working Group
The British Journal of Psychiatry, April 1, 2001; 178(4): 317 - 324.
[Abstract] [Full Text] [PDF]